Moreover, a synergistic effect is noted when combining TKIs with other kinase inhibitors or immunotherapy, as seen in metastatic melanoma and human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.